{
    "clinical_study": {
        "@rank": "163161", 
        "arm_group": {
            "arm_group_label": "Omega-3 polyunsaturated fatty acids", 
            "arm_group_type": "Experimental", 
            "description": "1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily"
        }, 
        "brief_summary": {
            "textblock": "The present study aims to examine the efficacy and safety of omega-3 polyunsaturated fatty\n      acids for pregnant women with depressive symptoms."
        }, 
        "brief_title": "The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO) in Tokyo: Open Trial", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pregnancy", 
            "Depression"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "Maternal depression can have a significant harmful influence on both mothers and children.\n      Considering the possibility of adverse effects of antidepressants and previous meta-analyses\n      showing the positive effects of omega-3 polyunsaturated fatty acids (PUFAs) supplementation\n      in reducing depressive symptoms, omega-3 PUFAs may provide a safe strategy. The\n      investigators evaluate efficacy and safety of omega-3 PUFAs for pregnant women with\n      depressive symptoms."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. pregnant women aged 20 years or older\n\n          2. between 12-24 weeks gestation\n\n          3. a Japanese conversational ability to understand the scope of the present trial\n\n          4. planned to return to the hospital for checkup at 4-6 weeks after childbirth\n\n          5. an Edinburgh Postnatal Depression Scale (EPDS) score is 9 or more\n\n          6. to have good physical health judged by obstetricians.\n\n        Exclusion Criteria:\n\n          1. history and current suspicion of psychosis or bipolar I disorder or substance-related\n             disorder or eating disorder or personality disorder\n\n          2. the item of EPDS concerning suicide ideation is 2 or more\n\n          3. other serious psychiatric symptoms such as self-harm behavior or in need of rapid\n             psychiatric treatment\n\n          4. difficult to expect a normal birth (ex: fetal malformation etc.)\n\n          5. having a history of bleeding disorder such as von Willebrand's Disease\n\n          6. regular treatment with aspirin or warfarin within the last 3 months\n\n          7. a smoking habit of \u226540 cigarettes per day\n\n          8. regular treatment with ethyl icosapentate or regular consumption of omega-3 PUFA\n             supplements within the last 3 months\n\n          9. a habit of eating fish  \u22654 times per week."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948596", 
            "org_study_id": "SYNCHRO-TMU-Open"
        }, 
        "intervention": {
            "arm_group_label": "Omega-3 polyunsaturated fatty acids", 
            "intervention_name": "Omega-3 polyunsaturated fatty acids", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "1200mg EPA and 600mg DHA daily"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pregnant women", 
            "depression", 
            "depressive symptoms"
        ], 
        "lastchanged_date": "May 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Toda", 
                        "country": "Japan", 
                        "state": "Saitama"
                    }, 
                    "name": "Toda Maternity Hospital"
                }, 
                "investigator": {
                    "last_name": "Daisuke Nishi, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "160-8402"
                    }, 
                    "name": "Tokyo Medical University"
                }, 
                "investigator": {
                    "last_name": "Daisuke Nishi, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO) in Tokyo: Open Trial", 
        "other_outcome": [
            {
                "measure": "gestational age", 
                "safety_issue": "No", 
                "time_frame": "at childbirth"
            }, 
            {
                "measure": "gestational diabetes mellitus", 
                "safety_issue": "Yes", 
                "time_frame": "4-6 weeks after childbirth"
            }, 
            {
                "measure": "gestational hypertension or preeclampsia", 
                "safety_issue": "Yes", 
                "time_frame": "4-6 weeks after childbirth"
            }, 
            {
                "measure": "induced labour", 
                "safety_issue": "Yes", 
                "time_frame": "at childbirth"
            }, 
            {
                "measure": "estimated blood loss", 
                "safety_issue": "Yes", 
                "time_frame": "at childbirth"
            }, 
            {
                "measure": "cesarean section", 
                "safety_issue": "Yes", 
                "time_frame": "at childbirth"
            }, 
            {
                "measure": "operative vaginal delivery", 
                "safety_issue": "Yes", 
                "time_frame": "at childbirth"
            }, 
            {
                "measure": "birthweight", 
                "safety_issue": "No", 
                "time_frame": "at childbirth"
            }, 
            {
                "measure": "one minute apger", 
                "safety_issue": "Yes", 
                "time_frame": "4-6 weeks after childbirth"
            }, 
            {
                "measure": "5-minute apgar", 
                "safety_issue": "Yes", 
                "time_frame": "4-6 weeks after childbirth"
            }, 
            {
                "measure": "neonatal intensive care unit admission", 
                "safety_issue": "Yes", 
                "time_frame": "4-6 weeks after childbirth"
            }, 
            {
                "measure": "cholesterol", 
                "safety_issue": "No", 
                "time_frame": "twelve weeks and 4-6 weeks after childbirth"
            }
        ], 
        "overall_contact": {
            "email": "d-nishi@ncnp.go.jp", 
            "last_name": "Daisuke Nishi, M.D., Ph.D.", 
            "phone": "81-42-341-2711", 
            "phone_ext": "6214"
        }, 
        "overall_official": {
            "affiliation": "Tokyo Medical University", 
            "last_name": "Daisuke Nishi, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "total score of the Hamilton Rating Scale for Depression (HAMD)", 
            "safety_issue": "Yes", 
            "time_frame": "Twelve weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948596"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tokyo Medical University", 
            "investigator_full_name": "Daisuke Nishi", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "total score of HAMD", 
                "safety_issue": "Yes", 
                "time_frame": "4-6 weeks after childbirth"
            }, 
            {
                "measure": "total scores on the Edinburgh Postnatal Depression Scale (EPDS)", 
                "safety_issue": "Yes", 
                "time_frame": "Twelve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "total score of the Beck Depression Inventory \u2161(BDI-\u2161)", 
                "safety_issue": "Yes", 
                "time_frame": "Twelve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "major depressive disorder (MDD) as determined by the depression module of the Mini International Neuropsychiatric Interview (MINI)", 
                "safety_issue": "Yes", 
                "time_frame": "Twelve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "omega-3 fatty acids concentrations in erythrocytes", 
                "safety_issue": "No", 
                "time_frame": "Tweve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "brain-derived neurotrophic factor (BDNF) in serum", 
                "safety_issue": "No", 
                "time_frame": "Twelve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "estrogen in plasma", 
                "safety_issue": "No", 
                "time_frame": "twelve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "oxytocin in plasma", 
                "safety_issue": "No", 
                "time_frame": "twelve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "progesterone in plasma", 
                "safety_issue": "No", 
                "time_frame": "twelve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "human chorionic gonadotropin (hCG) in plasma", 
                "safety_issue": "No", 
                "time_frame": "twelve weeks, 4-6 weeks after childbirth"
            }, 
            {
                "measure": "phospholipase A2 in plasma", 
                "safety_issue": "No", 
                "time_frame": "twelve weeks, 4-6 weeks after childbirth"
            }
        ], 
        "source": "Tokyo Medical University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Japan Society for the Promotion of Science (JSPS)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Toyama", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chiba University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Tokyo Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}